These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 7665722)

  • 1. Relationship between antipyrine metabolism and acetylation phenotype in health and chronic liver diseases.
    el-Yazigi A; Raines DA; Wahab FA; Sieck JO; Ernst P; Ali H; Dossing M
    J Clin Pharmacol; 1995 Jun; 35(6):615-21. PubMed ID: 7665722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenetic differences in the inhibitory effect of cimetidine on the metabolism of antipyrine.
    Gachályi B; Vas A; Csillag K; Nagy B; Kocsis F; Káldor A
    Eur J Clin Pharmacol; 1987; 31(5):613-5. PubMed ID: 3830247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antipyrine as a probe for human oxidative drug metabolism: identification of the cytochrome P450 enzymes catalyzing 4-hydroxyantipyrine, 3-hydroxymethylantipyrine, and norantipyrine formation.
    Engel G; Hofmann U; Heidemann H; Cosme J; Eichelbaum M
    Clin Pharmacol Ther; 1996 Jun; 59(6):613-23. PubMed ID: 8681486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between the metabolism of antipyrine, hexobarbital and theophylline in patients with liver disease as assessed by a 'cocktail' approach.
    Schellens JH; Janssens AR; van der Wart JH; van der Velde EA; Breimer DD
    Eur J Clin Invest; 1989 Oct; 19(5):472-9. PubMed ID: 2511024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antipyrine elimination and hepatic microsomal enzyme activity in patients with liver disease.
    Wensing G; Ohnhaus EE; Hoensch HP
    Clin Pharmacol Ther; 1990 Jun; 47(6):698-705. PubMed ID: 2113450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between metabolic clearance rate of antipyrine and hepatic microsomal drug-oxidizing enzyme activities in humans without liver disease.
    Vuitton D; Miguet JP; Camelot G; Delafin C; Joanne C; Bechtel P; Gillet M; Carayon P
    Gastroenterology; 1981 Jan; 80(1):112-8. PubMed ID: 7450397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Monooxigenase activity in liver diseases (study based on data of antipyrine metabolism)].
    Loginov AS; Bendikov EA; Kel'nia ZhA; Petrakov AV
    Ter Arkh; 1987; 59(2):84-9. PubMed ID: 3576485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the influence of diabetes mellitus on antipyrine metabolism and CYP1A2 and CYP2D6 activity.
    Matzke GR; Frye RF; Early JJ; Straka RJ; Carson SW
    Pharmacotherapy; 2000 Feb; 20(2):182-90. PubMed ID: 10678296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug acetylation in liver disease.
    Levy M; Caraco Y; Geisslinger G
    Clin Pharmacokinet; 1998 Mar; 34(3):219-26. PubMed ID: 9533983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of flumethrin on hepatic drug-metabolizing enzymes and antipyrine disposition in rats.
    Anadón A; Martinez-Larrañaga MR; Diaz MJ; Bringas P; Fernandez MC; Martinez MA; Fernandez-Cruz ML
    Toxicol Appl Pharmacol; 1995 May; 132(1):14-8. PubMed ID: 7747277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of the human hepatic cytochromes P450 involved in the in vitro oxidation of antipyrine.
    Sharer JE; Wrighton SA
    Drug Metab Dispos; 1996 Apr; 24(4):487-94. PubMed ID: 8801065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Studies on in vitro antipyrine metabolism by 13C,15N double labeled method.
    Nakagawa A; Nakamura K; Maeda K; Kamataki T; Kato R
    Life Sci; 1987 Jul; 41(2):133-43. PubMed ID: 3298908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acetylator phenotyping: the urinary caffeine metabolite ratio in slow acetylators correlates with a marker of systemic NAT1 activity.
    Cribb AE; Isbrucker R; Levatte T; Tsui B; Gillespie CT; Renton KW
    Pharmacogenetics; 1994 Jun; 4(3):166-70. PubMed ID: 7920698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accuracy and clinical utility of simplified tests of antipyrine metabolism.
    Farrell GC; Zaluzny L
    Br J Clin Pharmacol; 1984 Oct; 18(4):559-65. PubMed ID: 6487495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antipyrine clearance and metabolite formation: the influence of liver volume and smoking.
    Spoelstra P; Teunissen MW; Janssens AR; Weeda B; van Duijn W; Koch CW; Breimer DD
    Eur J Clin Invest; 1986 Aug; 16(4):321-7. PubMed ID: 3093244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antipyrine clearance and metabolite formation in patients with alcoholic cirrhosis.
    Teunissen MW; Spoelstra P; Koch CW; Weeda B; van Duyn W; Janssens AR; Breimer DD
    Br J Clin Pharmacol; 1984 Nov; 18(5):707-15. PubMed ID: 6508980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antipyrine metabolism during hepatic regeneration in the rat.
    Poulsen HE; Pilsgaard H
    Liver; 1985 Aug; 5(4):196-9. PubMed ID: 4058271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Substrate-selective inhibition by verapamil and diltiazem: differential disposition of antipyrine and theophylline in humans.
    Abernethy DR; Egan JM; Dickinson TH; Carrum G
    J Pharmacol Exp Ther; 1988 Mar; 244(3):994-9. PubMed ID: 3252045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation between antipyrine metabolite formation and theophylline metabolism in humans after simultaneous single-dose administration and at steady state.
    Teunissen MW; De Leede LG; Boeijinga JK; Breimer DD
    J Pharmacol Exp Ther; 1985 Jun; 233(3):770-5. PubMed ID: 4009489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antipyrine clearance and metabolite excretion in Saudi patients with non-alcoholic chronic liver disease.
    Ali HA; El-Yazigi A; Sieck JO; Ali MA; Dossing M; Raines DA; Saour J; Ernst P; Khan B
    Ann Saudi Med; 1995 Sep; 15(5):473-7. PubMed ID: 17590644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.